PharmaCyte Biotech, Inc. Schedules 2024 Annual Meeting of Stockholders

TL;DR

<b>PharmaCyte Biotech, Inc. will hold its 2024 annual meeting virtually on April 29, 2024, to elect directors, ratify auditors, and vote on executive compensation.</b>

AI Summary

PharmaCyte Biotech, Inc. (PMCB) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. Annual meeting to be held virtually via live audio webcast on April 29, 2024, at 11:00 a.m. EST. Stockholders will elect five persons to the board of directors. Proposal to ratify the appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending April 30, 2024. Proposal to approve, on an advisory basis, the compensation of named executive officers. No in-person attendance will be permitted; virtual attendance requires registration at http://www.viewproxy.com/PMCB/2024.

Why It Matters

For investors and stakeholders tracking PharmaCyte Biotech, Inc., this filing contains several important signals. The shift to a virtual meeting aims to increase stockholder attendance and participation globally, improve efficiency, and reduce costs and environmental impact. Key proposals include director elections, ratification of Marcum LLP as auditors, and an advisory vote on executive compensation, with the board recommending approval for all.

Risk Assessment

Risk Level: — PharmaCyte Biotech, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information, indicating low immediate risk.

Analyst Insight

Stockholders should review the proxy materials to understand the director nominees, auditor ratification, and executive compensation details before the April 29, 2024 meeting.

Key Numbers

• 5 — Directors to be elected (At the annual meeting)
• 2024-04-29 — Annual Meeting Date (Virtual meeting date)
• 11:00 a.m. EST — Meeting Time (Virtual meeting time)

Key Players & Entities

• PharmaCyte Biotech, Inc. (company) — Registrant name
• Marcum LLP (company) — Independent registered public accounting firm
• April 29, 2024 (date) — Annual meeting date
• April 30, 2024 (date) — Fiscal year end
• 20240327 (date) — Filing date

FAQ

Risk Factors

• Virtual Meeting Format [low — operational]: The annual meeting will be held virtually, with no in-person attendance option, requiring stockholders to register online to participate.

Industry Context

PharmaCyte Biotech operates in the biotechnology sector, focusing on pharmaceutical development.

Regulatory Implications

The filing is a standard DEF 14A (Definitive Proxy Statement) filed under the Securities Exchange Act of 1934, outlining corporate governance matters for stockholders.

What Investors Should Do

1. Review the list of director nominees and their qualifications.
2. Evaluate the rationale for ratifying Marcum LLP as the independent auditor.
3. Understand the details of the executive compensation plan and the advisory vote outcome.

Key Dates

• 2024-04-29: Annual Meeting of Stockholders — Election of directors, ratification of auditors, advisory vote on executive compensation.

Year-Over-Year Comparison

This filing is a Definitive Proxy Statement (DEF 14A) for the 2024 annual meeting, a routine disclosure for public companies.

Filing Documents

• pharm_def14a.htm (DEF 14A) — 338KB
• image_006.jpg (GRAPHIC) — 350KB
• image_007.jpg (GRAPHIC) — 610KB
• 0001683168-24-001762.txt (&nbsp;) — 1663KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 MANAGEMENT AND CORPORATE GOVERNANCE 10 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 17 PAY VERSUS PERFORMANCE 24 EQUITY COMPENSATION PLAN INFORMATION 28 REPORT OF AUDIT COMMITTEE 29 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 30 PROPOSAL NO. 1 - ELECTION OF DIRECTORS 31 PROPOSAL NO. 2 - RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 32 PROPOSAL NO. 3 - ADVISORY VOTE ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY STATEMENT 34 CODE OF CONDUCT AND ETHICS 35 OTHER MATTERS 35 STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR 35 PHA RMACYTE BIOTECH, INC. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, Nevada 89169 PROXY STATEMENT FOR THE PHARMACYTE BIOTECH, INC. ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 29, 2024 This proxy statement, along with the accompanying notice of our annual meeting of stockholders, contains information about the annual meeting of stockholders of PharmaCyte Biotech, Inc. including any adjournments or postponements of the annual meeting. We are holding the annual meeting at 11:00 a.m. EST on Monday, April 29, 2024. You will be able to attend the annual meeting by first registering at http://www.viewproxy.com/PMCB/2024. You will receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. In this proxy statement, we refer to PharmaCyte Biotech, Inc. as &ldquo;PharmaCyte,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we&rdquo; and &ldquo;us.&rdquo; This proxy statement relates to the solicitation of proxies by our board of directors for use at the annual meeting. On or about April 1, 2024, we expect to begin sending this proxy statement, the attached Notice of Annual Meeting of Stockholders and the enclosed proxy card to all stockholders entitled to vote at the annual meeting. Although not part of this proxy statement, we

View Full Filing

View this DEF 14A filing on SEC EDGAR